Elena Popugaeva
Overview
Explore the profile of Elena Popugaeva including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
881
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zernov N, Ghamaryan V, Melenteva D, Makichyan A, Hunanyan L, Popugaeva E
Sci Rep
. 2024 Oct;
14(1):23512.
PMID: 39384900
Alzheimer disease (AD) is characterized by progressive loss of memory. Synaptic loss is now the best correlate of cognitive dysfunction in patients with Alzheimer's disease. Thus, restoration or limitation of...
2.
Zernov N, Popugaeva E
Int J Mol Sci
. 2023 Oct;
24(20).
PMID: 37895105
The transient receptor potential cation channel, subfamily C, member 6 (TRPC6), has been believed to adjust the formation of an excitatory synapse. The positive regulation of TRPC6 engenders synapse enlargement...
3.
Zernov N, Veselovsky A, Poroikov V, Melentieva D, Bolshakova A, Popugaeva E
Int J Mol Sci
. 2022 Nov;
23(21).
PMID: 36362339
Synapse loss in the brain of Alzheimer's disease patients correlates with cognitive dysfunctions. Drugs that limit synaptic loss are promising pharmacological agents. The transient receptor potential cation channel, subfamily C,...
4.
Zernov N, Ghamaryan V, Makichyan A, Melenteva D, Hunanyan L, Popugaeva E
Curr Issues Mol Biol
. 2022 Nov;
44(11):5191-5208.
PMID: 36354665
Alzheimer's disease (AD) is characterized by synaptic dysfunction, which is expressed through the loss of dendritic spines and changes in their morphology. Pharmacological compounds that are able to protect spines...
5.
Zernov N, Bezprozvanny I, Popugaeva E
IBRO Neurosci Rep
. 2022 Jan;
12:90-97.
PMID: 35079728
Calcium/calmodulin-dependent protein kinase II (CaMKII) and neuronal store-operated calcium entry (nSOCE) have been implicated in the development of Alzheimer's disease (AD). nSOCE is involved in regulation of dendritic spine shape,...
6.
Hunanyan L, Ghamaryan V, Makichyan A, Popugaeva E
Int J Mol Sci
. 2021 Dec;
22(24).
PMID: 34948414
Store-operated calcium entry (SOCE) constitutes a fine-tuning mechanism responsible for the replenishment of intracellular stores. Hippocampal SOCE is regulated by store-operated channels (SOC) organized in tripartite complex TRPC6/ORAI2/STIM2. It is...
7.
Popugaeva E
Curr Alzheimer Res
. 2021 Jan;
17(12):1065-1071.
PMID: 33463468
Alzheimer disease is the dominant form of elderly dementia. Today all clinical trials that target β-amyloid have failed to indicate that β-amyloid may not be a causative agent in AD...
8.
Prikhodko V, Chernyuk D, Sysoev Y, Zernov N, Okovityi S, Popugaeva E
Cells
. 2020 Oct;
9(11).
PMID: 33114455
Alzheimer's disease and cerebral ischemia are among the many causative neurodegenerative diseases that lead to disabilities in the middle-aged and elderly population. There are no effective disease-preventing therapies for these...
9.
Popugaeva E, Chernyuk D, Bezprozvanny I
Curr Alzheimer Res
. 2020 May;
17(4):344-354.
PMID: 32469698
Despite decades of research and effort, there is still no effective disease-modifying treatment for Alzheimer's Disease (AD). Most of the recent AD clinical trials were targeting amyloid pathway, but all...
10.
Chernyuk D, Zernov N, Kabirova M, Bezprozvanny I, Popugaeva E
Neuroscience
. 2019 May;
410:118-127.
PMID: 31055008
Alzheimer's disease (AD) is the neurodegenerative disorder with no cure. Recent studies suggest that dysregulated postsynaptic store-operated calcium entry (nSOCE) may underlie mushroom spine loss that is related to AD...